IMR Press / CEOG / Volume 38 / Issue 2 / pii/1630488779396-2033012105

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Is there any effect of fetal gender on the markers of first trimester Down's Syndrome screening?
Show Less
1 Department of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Idi-Araba, Lagos (Nigeria)
Clin. Exp. Obstet. Gynecol. 2011, 38(2), 162–164;
Published: 10 June 2011

Introduction: At present, the most effective trisomy 21-screening method is the estimate of risk combining maternal age, fetal nuchal translucency, beta-hCG and pregnancy-associated PAPP-A. Objective: The aim of this study was to investigate the possible effect of fetal gender in first trimester Down's syndrome screening markers. Design: Retrospective study. Setting: Prenatal Diagnosis Centre in a tertiary hospital in I agos. Methods: Of a total of 350 pregnancies in which fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A were performed were included in this study. These markers were investigated to see if they differed on the basis of fetal gender. Results: PAPP-A levels were higher in female fetuses although the difference was not statistically significant. Nuchal translucency was 0.099 mm more in male fetuses. Conclusion: The results suggest that first trimester markers differ on gender but are of no clinical significance, confirming the result of other authors.
Down's syndrome
Nuchal translucency
Back to top